


Supplementary Table 1. Primary diseases

Primary diseases	Hydroxyzine (n=71)	Haloperidol (n=82)	Total (n=153)
Certain infectious and parasitic diseases	2 (2.8)	2 (2.4)	4 (2.6)
Neoplasms	23 (32.4)	26 (31.7)	49 (32.0)
Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism	1 (1.4)	2 (2.4)	3 (2.0)
Endocrine, nutritional and metabolic diseases	1 (1.4)	2 (2.4)	3 (2.0)
Diseases of the nervous system	4 (5.6)	2 (2.4)	6 (3.9)
Diseases of the circulatory system	4 (5.6)	9 (11.0)	13 (8.5)
Diseases of the respiratory system	13 (18.3)	15 (18.3)	28 (18.3)
Diseases of the digestive system	13 (18.3)	12 (14.6)	25 (16.3)
Diseases of the skin and subcutaneous tissue	1 (1.4)	1 (1.2)	2 (1.3)
Diseases of the musculoskeletal system and connective tissue	0	1 (1.2)	1 (0.7)
Diseases of the genitourinary system	5 (7.0)	0	5 (3.3)
Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified	0	4 (4.9)	4 (2.6)
Injury, poisoning and certain other consequences of external causes	2 (2.8)	5 (6.1)	7 (4.6)
Codes for special purposes (COVID-19)	1 (1.4)	0	1 (0.7)
Hospitalization for medical examination	1 (1.4)	1 (1.2)	2 (1.3)

Values are presented as n (%)

Supplementary Figure 1. Number of patients for whom hydroxyzine or haloperidol was used by year

(a) Hydroxyzine



(b) Haloperidol

